PolitiKit

Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Free trade agreements as they relate to the biopharmaceutical industry.

Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities

Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.

Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).

Provide input on a national strategy for drugs for rare diseases.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Recommend the creation of a Chief Patient Officer.

Provide input on pharmacare.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend the creation of a Patient Ombudsman.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input regarding Canada’s pharmaceutical sovereignty.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Support input into the consultation on draft guidance on decentralized clinical trials.

Discussions and feedback regarding regulatory efficiency, including environmental assessments, the federal carbon charge, the Clean Fuel Standard, methane regulations, Clean Electricity Regulations, and the output-based pricing system.

Discussions regarding climate policies and initiatives, including the federal carbon charge, the Clean Fuel Standard, methane regulations, and the output-based pricing system, as well as policy supports for innovations that reduce greenhouse gas emissions (including Renewable Natural Gas, Compressed Natural Gas, CCUS, hydrogen and power-to-gas).

Discussions regarding projects, expansions, optimizations, and changes to tolling arrangements relating to Enbridge’s liquids pipelines, natural gas pipelines, and utilities and power assets.

Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Lobbying to amend the Copyright Modernization Act. Amend the section (old section 21) to limit fair dealing exemption for education.

Increase funding to the Canada Book Fund and maintain all other programs that support writing and publishing in Canada.

To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.

To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.

To actively promote the enhancement of publicly funded women’s health initiatives/programs.

Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs.

To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

Policies or programs related to access to care and potential treatments for the ALS Community.